Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 236 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine-naloxone Clear all
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals

NCT03711318
View directory record Official record
Conditions
Heroin Dependence
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 13, 2026, 5:38 PM EDT
Terminated Phase 3 Interventional Results available

Virginia Opioid Overdose Treatment InitiatVE

NCT03818399
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
SUBLOCADE
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Medication Maintenance Therapy in Community Pharmacy Settings

NCT03766893
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine / Naloxone Oral Product, injectable naltrexone, Pharmacy maintenance addiction care
Drug · Other
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence

NCT00134914
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 1998
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients

NCT02093559
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Overdose
Interventions
Brief counseling Intervention
Behavioral
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Early Phase 1 Interventional

Feasibility of the Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid Withdrawal

NCT03489161
View directory record Official record
Conditions
Drug Overdose, Opioid Withdrawal, Opioid-use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

NCT02044094
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, buprenorphine and naloxone, hydromorphone, placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

Dane County Drug Court Study for Addicted Offenders

NCT01843751
View directory record Official record
Conditions
Opioid Dependence
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 13, 2026, 5:38 PM EDT
Recruiting Phase 4 Interventional

A Bundled Intervention to End Opioid Overdoses

NCT07485335
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Overdose
Interventions
Bundled intervention (Experimental), control group, Buprenorphine (Experimental), Scheduled Peer Support Specialist (Experimental), Telemedicine Buprenorphine Treatment
Other · Drug · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Results available

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

NCT02032433
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Extended-Release Naltrexone, Buprenorphine-Naloxone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Tarzana, California • Jacksonville, Florida • Rockville, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 13, 2026, 5:38 PM EDT
Withdrawn Phase 2 Interventional

Evaluation of a Compliance Marker in Prescription Opioid Abusers With Chronic Pain

NCT02276989
View directory record Official record
Conditions
Compliance, Chronic Pain
Interventions
acetazolamide, Quinine, Riboflavin
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 13, 2026, 5:38 PM EDT
Not listed No phase listed Observational

Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing

NCT05307458
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Withdrawal
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
United Health Services Hospitals, Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Binghamton, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 13, 2026, 5:38 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Multi-System Analysis of Opioid Receptor Binding

NCT05528848
View directory record Official record
Conditions
Healthy, Opioid Use Disorder
Interventions
Carfentanil, C-11, Naloxone, Loperamide Hydrochloride
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Optimizing Outcomes Using Suboxone for Opiate Dependence

NCT00591617
View directory record Official record
Conditions
Opioid Dependency
Interventions
Psychosocial treatment plus Suboxone pharmacotherapy
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
15 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence

NCT02496403
View directory record Official record
Conditions
Opiate Substitution Treatment
Interventions
Standard Medical Management (SMM)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Not applicable Interventional

SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence

NCT04080180
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Contingency Management, Brief Motivational Interviewing + Substance Free Activities + Mindfulness
Behavioral
Lead sponsor
Karen Derefinko, PhD
Other
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

NCT01908842
View directory record Official record
Conditions
Opioid Dependence, on Agonist Therapy
Interventions
BNX sublingual tablets, BNX sublingual film, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Baldwin County, Alabama • Houston County, Alabama • Maricopa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia

NCT00539123
View directory record Official record
Conditions
Opiate Dependence
Interventions
behavioral drug and HIV risk reduction counseling (BDRC), abstinence-contingent buprenorphine (ACB)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

NCT01262092
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions
Buprenorphine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 4 Interventional

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

NCT04276259
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
Buprenorphine, Naltrexone, Oral Placebo, IM Placebo, Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.
Drug · Device
Lead sponsor
Marta Peciña, MD PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Not applicable Interventional Results available

Emergency Department Longitudinal Integrated Care

NCT03699085
View directory record Official record
Conditions
Opioid-use Disorder, Emergency Department
Interventions
ED-LINC
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 13, 2026, 5:38 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

NCT07314346
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Hollywood, Florida • Overland Park, Kansas • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Results available

Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence

NCT00555425
View directory record Official record
Conditions
Opiate Dependence
Interventions
Behavioral: Buprenorphine/naloxone maintenance (Mtn), Behavioral: Buprenorphine/naloxone detoxification (Dtx)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 13, 2026, 5:38 PM EDT
Completed No phase listed Observational

Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV

NCT03976258
View directory record Official record
Conditions
HIV Infection, Opioid-use Disorder, Cardiovascular Diseases
Interventions
buprenorphine/naloxone, Methadone, Naltrexone Injection, Heroin
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 13, 2026, 5:38 PM EDT